As reported previously, Reed Maurer passed away on August 30 due to complications from pneumonia. He was approaching his 84th birthday.Reed has been a driver of the international pharma community in Japan like nobody else. Arriving over fifty years ago…
ACADEMIA
Oita University to Begin PI Study for Replicon RNA Vaccine in October
Oita University plans to start a first-in-human PI clinical trial for its replicon RNA vaccine against COVID-19 in the middle of October. It hopes to confirm the vaccine’s safety and immunogenicity in PI, with an eye to the launch of…
To read the full story
Related Article
ACADEMIA
- Use Oral Dexamethasone for COVID-19 Patients Requiring Oxygen: Scientific Societies
September 10, 2021
- Systemic Symptoms Unlikely to Occur from Contaminated Moderna Jabs: Japan Vaccinology Society
September 9, 2021
- Darzquro Expected to Treat 900 AL Amyloidosis Patients in Japan Annually: Specialist
September 6, 2021
- 1st COVID-19 Delta Variant Mutation Found in Japan: TMDU
August 31, 2021
- TMDU, Takeda Running Joint Research on Heteroduplex Oligonucleotide for Neuro Diseases
August 24, 2021
Over two years after the rollout of the cost-effectiveness assessment (CEA) scheme in April 2019, discussions on its system reform are set to go into full swing at a key reimbursement policy council known as Chuikyo. Both payer and healthcare…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…